Literature DB >> 28277836

Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments.

Gillian A Horne1, Mhairi Copland1.   

Abstract

INTRODUCTION: Self-renewal is considered a defining property of stem cells. Self-renewal is essential in embryogenesis and normal tissue repair and homeostasis. However, in cancer, self-renewal pathways, e.g. WNT, NOTCH, Hedgehog and BMP, frequently become de-regulated in stem cells, or more mature progenitor cells acquire self-renewal properties, resulting in abnormal tissue growth and tumorigenesis. Areas covered: This review considers the conserved embryonic self-renewal pathways, including WNT, NOTCH, Hedgehog and BMP. The article describes recent advances in our understanding of these pathways in leukemia and, more specifically, leukemia stem cells (LSC), how these pathways cross-talk and interact with the LSC microenvironment, and discusses the clinical implications and potential therapeutic strategies, both in preclinical and in clinical trials for hematological malignancies. Expert opinion: The conserved embryonic self-renewal pathways are frequently de-regulated in cancer stem cells (CSC), including LSCs. There is significant cross-talk between self-renewal pathways, and their downstream targets, and the microenvironment. Effective targeting of these pathways is challenging due to cross-talk, and importantly, because these pathways are important for normal stem cells as well as CSC, adverse effects on normal tissues may mean a therapeutic window cannot be identified. Nonetheless, several agents targeting these pathways are currently in clinical trials in hematological malignancies.

Entities:  

Keywords:  Hedgehog; Notch; Self-renewal; Wnt; bone morphogenic protein; cancer stem cell; leukemia stem cell; microenvironment

Mesh:

Substances:

Year:  2017        PMID: 28277836     DOI: 10.1080/17460441.2017.1303477

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  6 in total

1.  Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD+ acute myeloid leukemia.

Authors:  Dan Li; Tongjuan Li; Zhen Shang; Lei Zhao; Qian Xu; Jiaqi Tan; Yun Qin; Yuanyuan Zhang; Yang Cao; Na Wang; Liang Huang; Xiaojian Zhu; Kuangguo Zhou; Liting Chen; Chunrui Li; Ting Xie; Yi Yang; Jue Wang; Jianfeng Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-03-13

Review 2.  Developing therapeutic approaches for chronic myeloid leukemia: a review.

Authors:  Veerandra Kumar; Malkhey Verma
Journal:  Mol Cell Biochem       Date:  2022-10-10       Impact factor: 3.842

3.  Pin2 telomeric repeat factor 1-interacting telomerase inhibitor 1 (PinX1) inhibits nasopharyngeal cancer cell stemness: implication for cancer progression and therapeutic targeting.

Authors:  Chaosheng Yu; Fang Chen; Xiaoqi Wang; Zhimou Cai; Mengxue Yang; Qingwen Zhong; Jialian Feng; Junzheng Li; Congxiang Shen; Zhong Wen
Journal:  J Exp Clin Cancer Res       Date:  2020-02-07

Review 4.  Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue-Going Beyond Apoptosis Induction.

Authors:  Daniel Heudobler; Florian Lüke; Martin Vogelhuber; Sebastian Klobuch; Tobias Pukrop; Wolfgang Herr; Christopher Gerner; Pan Pantziarka; Lina Ghibelli; Albrecht Reichle
Journal:  Front Oncol       Date:  2019-12-20       Impact factor: 6.244

5.  Inhibition of Bone Morphogenetic Protein 2 Suppresses the Stemness Maintenance of Cancer Stem Cells in Hepatocellular Carcinoma via the MAPK/ERK Pathway.

Authors:  Juncheng Guo; Min Guo; Jinfang Zheng
Journal:  Cancer Manag Res       Date:  2021-01-27       Impact factor: 3.989

6.  Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD+ acute myeloid leukemia.

Authors:  Dan Li; Tongjuan Li; Zhen Shang; Lei Zhao; Qian Xu; Jiaqi Tan; Yun Qin; Yuanyuan Zhang; Yang Cao; Na Wang; Liang Huang; Xiaojian Zhu; Kuangguo Zhou; Liting Chen; Chunrui Li; Ting Xie; Yi Yang; Jue Wang; Jianfeng Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-03-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.